Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li Di

Showing results (291-300 of 293) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 293 results.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2020
Pseudouridylation defect due to <i>DKC1</i> and <i>NOP10</i> mutations causes nephrotic syndrome with cataracts, hearing impairment, and enterocolitisEszter Balogh, Jennifer C Chandler, Máté Varga, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 30

Showing results (291-300 of 293) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 293 results.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2020
Pseudouridylation defect due to <i>DKC1</i> and <i>NOP10</i> mutations causes nephrotic syndrome with cataracts, hearing impairment, and enterocolitisEszter Balogh, Jennifer C Chandler, Máté Varga, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 30